Press Room

Alesta Therapeutics, a CMTA-STAR Alliance Partner focused on developing therapies for rare diseases, recently announced a successful financing that will allow them to address CMT through its innovative therapeutic candidate, ALE2. According to the company, ...

Charcot-Marie-Tooth disease (CMT) is the most common inheritable peripheral neuropathy, affecting millions of people worldwide. Despite its prevalence, many people are unfamiliar with CMT and its impact. That’s why CMTA created a new video to explain ...

What is the Nervosave Survey? CMTA-STAR Alliance Partner Nervosave Therapeutics, a France-based biotech company, is seeking participants for an online survey to understand patient perspectives on a new genetic therapy under development for CMT1A. According to ...

NMD Pharma A/S, a CMTA-STAR Alliance Partner, recently announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to NMD670, the investigational drug the company is studying in its ongoing ...

The Simply CMT Podcast is presented by the Charcot-Marie-Tooth Association. This monthly podcast highlights the CMT community and the work of CMTA. Simply CMT. Empowering Patients, Accelerating Research. Simplified. Interested in being a guest? Email marketing@cmtausa.org View ...